Research goal: Nectin-2 (Nec2) is an adhesion molecule with a significant role in the immune response. Elevated expression of Nec2 in many solid tumors is pressumed to play a role in cancer development through evasion of immune surveillance. Interactions of Nec2 with the immune system make this molecule a promising target for targeted immunotherapy aimed at regulating the immune response against tumor cells. Research on breast cancer cells determined an increased level of genetic and protein expression of Nec2, but in a limited group of patients. The current study aims to complete the previous findings by quantifying the expression of membrane Nec2 in a larger group of patients and to establish the connec-tion between the expression of Nec2 and the clinical and pathological data of the patients. Materials and methods: Samples of breast biopsies of female patients along with corresponding clinical and pathological data were collected from the archives of the Department of Pathology and Cytology, Rijeka Clinical Hospital Center. From a total of 131 samples, tissue microarrays (TMA) were made and immunohistochemical staining of membrane Nec2 was performed. In order to quantify the level of Nec2 expressed on cell membranes, the H-score parameter was used to assess immunoreactivity. Results: A high incidence of Nec2 positive breast cancer samples was ob-served. Although Nec2 expression was also observed in non-tumor samples, the level of expressed Nec2 was significantly higher in tumor samples. No statistically significant dependence of Nec2 expression and following clinical and pathological data was observed: type of cancer, size of cancer tissue, age and hormonal/HER2 status. Conclusion: The results show an increased level of expressed Nec2 in breast cancer tissues compared to healthy tissue, however, no link between Nec2 expression and any clinical-pathological parameters of the patients was observed.